Illumina Stock Price, News & Analysis

Illumina, Inc. (NASDAQ: ILMN) operates in the analytical laboratory instrument manufacturing industry and is widely described as a global leader in DNA sequencing and array-based technologies. According to the company’s own statements in multiple press releases, Illumina focuses on improving human health by unlocking the power of the genome and serves customers across research, clinical, and applied markets.

Illumina states that its products and technologies are used in life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides tools and services to analyze genetic material, and Polygon data notes that Illumina generates a substantial portion of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms, while lower-throughput tools support applications that require smaller data outputs, such as certain screening uses. Illumina also sells microarrays that enable focused genetic screening for consumer and agricultural applications.

Core business and technology focus

Illumina’s business centers on DNA sequencing and array-based technologies that support genomic and multiomic research. Company descriptions in recent news releases emphasize that Illumina is building foundational technologies and datasets for genomics, including single-cell and multiomic analysis, and that its platforms are used by customers in research laboratories, clinical environments, and applied markets.

Polygon data indicates that more than 90% of Illumina’s revenue historically has come from sequencing instruments, consumables, and services, with microarrays accounting for a smaller share. This highlights a business model built around instrument placement and the ongoing use of consumables and associated services for genomic analysis.

Applications across research, clinical, and applied markets

In company press releases, Illumina explains that its technologies are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Examples cited by Illumina include use in cancer research and oncology, reproductive and preventive health, and agricultural and population-scale studies. The company also notes that it partners with biopharma, academic institutions, and population health programs to generate large genomic and proteomic datasets.

Illumina’s recent initiatives underscore its role in enabling precision medicine and drug discovery. In its announcement of the Illumina Billion Cell Atlas, the company describes building a large genome-wide genetic perturbation dataset intended to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Atlas is designed to help validate genetic targets, train AI models at scale, and advance research into disease mechanisms across immune disorders, cancer, cardiometabolic, neurological, and rare genetic diseases.

Multiomics, AI, and data products

Illumina’s news releases describe a growing focus on multiomics and AI-enabled analysis. The company has introduced Illumina Connected Multiomics, a cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale. According to Illumina, this platform integrates data across transcriptomics, genomics, proteomics, epigenetics, and other modalities, and uses integrated DRAGEN secondary analysis and AI-enabled variant interpretation tools such as PrimateAI and PromoterAI to highlight biologically meaningful signals.

Illumina has also launched its BioInsight business, which the company describes as providing foundational technologies and datasets to power the next generation of drug discovery and AI in pharma. The Illumina Billion Cell Atlas is identified as the first data product from BioInsight, built using Illumina’s single-cell RNA preparation platform and processed through the DRAGEN pipeline and Illumina Connected Analytics cloud platform.

Proteomics and expansion into the proteomics market

Illumina is expanding into proteomics, as detailed in company news about Illumina Protein Prep. The company states that Illumina Protein Prep delivers broad coverage of the blood proteome and is being used by customers ranging from academic institutions to large national biobanks. Illumina positions Protein Prep as a way to integrate comprehensive proteomics into large-scale genomics studies, enriching datasets for diseases such as cancer and cardiometabolic and immunologic conditions.

Illumina further notes that it is acquiring Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic, under a Stock Purchase Agreement described in a Form 8-K filing. The company states that this acquisition will add aptamer-based and functional proteomics capabilities, subject to regulatory approvals and customary closing conditions.

Strategic collaborations and partnerships

Illumina’s press releases highlight collaborations with major pharmaceutical and genomics companies. For the Billion Cell Atlas, Illumina describes an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company as founding participants, with the goal of using large-scale cell perturbation data to validate drug targets and train AI models. Another release details a collaboration and strategic investment with MyOme, a genomics innovation and risk modeling company, aimed at advancing whole-genome sequencing combined with AI-integrated risk models for common, chronic conditions, cancers, and rare diseases.

These collaborations illustrate Illumina’s role as a technology and data provider to biopharma, clinical genomics, and population health initiatives, leveraging its sequencing platforms, proteomics solutions, and AI-enabled analytics.

Capital markets and regulatory filings

Illumina’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Stock Market LLC under the symbol ILMN, as disclosed in multiple Form 8-K filings. The company is incorporated in Delaware, with a stated jurisdiction of incorporation of Delaware and an employer identification number listed in its SEC filings. Recent 8-K filings describe periodic financial results announcements, preliminary unaudited results, and capital markets transactions, including the issuance of 4.750% notes due 2030 under an existing indenture.

In an 8-K dated November 25, 2025, Illumina reports the completion of a public offering of notes and states that it expects to use the net proceeds for general corporate purposes, which may include repayment of existing notes and completion of the proposed SomaLogic acquisition. Another 8-K dated June 22, 2025 outlines the Stock Purchase Agreement to acquire SomaLogic and related entities, including details on the purchase price, potential milestone payments, and regulatory approval conditions.

Company status and sector classification

Based on the most recent SEC filings and press releases provided, Illumina remains an active public company with securities registered under Section 12(b) of the Exchange Act and trading on Nasdaq under the symbol ILMN. The company is classified in the analytical laboratory instrument manufacturing industry within the broader manufacturing sector, and its disclosures emphasize its role in genomics, multiomics, and proteomics technologies.

Use cases for investors and researchers

For investors, Illumina represents a company whose business is closely tied to the adoption and expansion of genomic, multiomic, and proteomic technologies in research, clinical, and applied markets. Its SEC filings provide details on financial performance, capital structure, and material agreements, while its press releases describe product launches, collaborations, and strategic initiatives in sequencing, multiomics software, proteomics, and AI-enabled data products.

For researchers and industry participants, Illumina’s platforms and datasets, such as Illumina Connected Multiomics, DRAGEN pipelines, Illumina Protein Prep, and the Billion Cell Atlas, are positioned by the company as tools to accelerate discovery, support precision medicine, and enable large-scale studies across diverse diseases and populations.